JAMA Cardiology
Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis of randomised trialsInterventions
Declared ties to: Boehringer Ingelheim, Eli Lilly for the EMPA-KIDNEY, Novo Nordisk for the ASCEND-PLUS and 1 more
- Intensive blood pressure lowering
- Chronic kidney disease
- Cardiovascular disease
- Kidney failure
- Estimated glomerular filtration rate
- Humans
The paper
Aristotle University of Thessaloniki; Churchill Hospital
JAMA Cardiology, 7 Oct 2026


